Scilex Holding (SCLXW) Other Non-Current Liabilities (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Other Non-Current Liabilities of $25.5 million in Q1 2026, up 14578.74% quarter-over-quarter from $174000.0 in Q4 2025, and down 53.38% on a YoY basis from $54.8 million in Q1 2025.
Scilex Holding (SCLXW) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding's Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $25.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 53.38% year-over-year to $25.5 million; the TTM figure through Mar 2026 stood at $25.5 million (down 53.38% YoY), while the FY2025 annual figure was $174000.0, down 82.6% from the prior year.
- Other Non-Current Liabilities was $25.5 million for Q1 2026 at Scilex Holding, up from $174000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $82.0 million in Q3 2025 to a low of $76788.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $11.9 million across 5 years, with a median of $1.5 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 97.88% in 2022, then surged 8344.03% in 2023.
- A 5-year view of Other Non-Current Liabilities shows it stood at $1.2 million in 2022, then gained by 23.31% to $1.5 million in 2023, then slumped by 34.12% to $1.0 million in 2024, then slumped by 82.6% to $174000.0 in 2025, then jumped by 14578.74% to $25.5 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $25.5 million (Q1 2026), $174000.0 (Q4 2025), and $82.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.54 Mn |
| Dec 31, 2025 | 174,000.00 |
| Sep 30, 2025 | 81.98 Mn |
| Jun 30, 2025 | 165,000.00 |
| Mar 31, 2025 | 54.79 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 11.45 Mn |
| Jun 30, 2024 | 187,000.00 |
| Mar 31, 2024 | 6.94 Mn |
| Dec 31, 2023 | 1.52 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 6.57 Mn |
| Mar 31, 2023 | 6.48 Mn |
| Dec 31, 2022 | 1.23 Mn |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 76,788.00 |
| Dec 31, 2021 | 35.70 Mn |
| Sep 30, 2021 | 4.86 Mn |
| Jun 30, 2021 | 3.69 Mn |